Sign In
12 Aug 2011 10:00
12 August 2011
LSE : VER
NOTIFICATION OF TRANSACTIONS OF DIRECTORS, PERSONS DISCHARGING MANAGERIAL RESPONSIBILITY OR CONNECTED PERSONS
Vernalis plc ("Vernalis" or the "Company") announces that it has been informed that, on 11 August 2011, the following directors bought shares in the Company:
·; Mr Ian Garland, Chief Executive Officer, purchased 50,000 Ordinary 1 pence shares at a price of 37 pence per share.
·; Mr David Mackney, Chief Financial Officer, purchased 50,000 Ordinary 1 pence shares at a price of 37 pence per share.
Following this transaction, Mr Garland and Mr Mackney will be the beneficial holders of 141,953 Ordinary 1 pence shares (0.143 %) and 68,390 Ordinary 1 pence shares (0.069 %), respectively, of the Company's current issued share capital.
Enquiries:
Vernalis | +44 (0) 118 989 9360 |
Ian Garland, Chief Executive Officer David Mackney, Chief Financial Officer
| |
Brunswick Group | +44 (0) 20 7404 5959 |
Jon Coles Kristin Shine
| |
Taylor Rafferty | +44 (0) 20 7614 2900 |
Rob Newman Faisal Kanth |
About Vernalis:
Vernalis is a revenue generating development stage pharmaceutical company with significant expertise in taking promising product candidates along a commercially-focused path to market. The Group has one marketed product, frovatriptan for the acute treatment of migraine, and eight candidates in development, seven of which are designated priority programmes. Four of these priority development programmes are currently unpartnered and three are partnered. Pipeline programmes are derived from both our own research activities where we have significant expertise in fragment and structure based drug discovery, as well as from collaborations. Our technologies, capabilities and products are endorsed by collaborations with Endo, GSK, Lundbeck, Menarini, Novartis and Servier.
For further information about Vernalis, please visit www.vernalis.com.
Follow the stocks
